Your browser doesn't support javascript.
loading
Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study.
Bemer, Pascale; Peuchant, Olivia; Guet-Revillet, Hélène; Bador, Julien; Balavoine, Charlotte; Basille, Damien; Beltramo, Guillaume; Blanc, François-Xavier; Blanchard, Elodie; Boulanger, Sarah; Bourgoin, Anne; Boutoille, David; Cambau, Emmanuelle; Canis, Frédérique; Caparros, Didier; Carricajo, Anne; Carrière, Christian; Couetdic, Gérard; Couturaud, Francis; Dalphin, Jean-Charles; Degot, Tristan; Desquiens, Marion; Devouassoux, Gilles; Duez, Jean-Marie; Dumitrescu, Oana; Dupuy-Grasset, Magali; Gaudart, Alice; Georges, Marjolaine; Godet, Cendrine; Godreuil, Sylvain; Guillouzouic, Aurélie; Hamdad-Daoudi, Farida; Héry-Arnaud, Geneviève; Koebel, Christelle; Lagrange, Aurore; Lanotte, Philippe; Marchand-Adam, Sylvain; Mougari, Faïza; Murris, Marlène; Patry, Isabelle; Pérouse de Montclos, Michèle; Raskine, Laurent; Risso, Karine; Segonds, Christine; Sicard, Dominique; Terru, Dominique; Vachée, Anne; Vergnon, Jean-Michel; Martin, Christian; Schramm, Frédéric.
Afiliação
  • Bemer P; Department of Bacteriology, CHU Nantes, Nantes, France.
  • Peuchant O; Department of Bacteriology, CHU Bordeaux, Bordeaux, France.
  • Guet-Revillet H; Department of Bacteriology, CHU Toulouse, Toulouse, France.
  • Bador J; Department of Bacteriology, CHU Dijon, Dijon, France.
  • Balavoine C; Department of Respiratory Diseases, CHU Tours, Tours, France.
  • Basille D; Department of Respiratory Diseases, Amiens University Hospital, CHU Amiens, 80054, Amiens Cedex 1, France.
  • Beltramo G; EA 4294 AGIR, Picardie Jules Verne University, Amiens, France.
  • Blanc FX; Department of Respiratory Diseases, CHU Dijon, Dijon, France.
  • Blanchard E; Department of Respiratory Diseases, CHU Nantes, Nantes, France.
  • Boulanger S; Department of Respiratory Diseases, CHU Bordeaux, Bordeaux, France.
  • Bourgoin A; Department of Respiratory Diseases, CH Roubaix, Bordeaux, France.
  • Boutoille D; Department of Bacteriology, CHU Poitiers, Poitiers, France.
  • Cambau E; Department of Infectious Disease, CHU Nantes, Nantes, France.
  • Canis F; Department of Bacteriology, AP-HP, Paris, France.
  • Caparros D; Laboratoire Associé du Centre National de Référence des Mycobactéries et Résistance des Mycobactéries aux Antibiotiques (CNR-MyRMA), Paris, France.
  • Carricajo A; Department of Bacteriology, CH Valenciennes, Valenciennes, France.
  • Carrière C; Department of Respiratory Diseases, CH Valenciennes, Valenciennes, France.
  • Couetdic G; Department of Bacteriology, CHU Saint Etienne, Saint Etienne, France.
  • Couturaud F; Department of Bacteriology, CHU Montpellier, Montpellier, France.
  • Dalphin JC; Department of Bacteriology, CHU Besançon, Besançon, France.
  • Degot T; Department of Respiratory Diseases, CHU Brest, Brest, France.
  • Desquiens M; Department of Respiratory Diseases, CHU Besançon, Besançon, France.
  • Devouassoux G; Department of Respiratory Diseases, CHRU Strasbourg, Strasbourg, France.
  • Duez JM; Department of Respiratory Diseases, Amiens University Hospital, CHU Amiens, 80054, Amiens Cedex 1, France.
  • Dumitrescu O; Department of Respiratory Diseases, Hospices Civils Lyon, Lyon, France.
  • Dupuy-Grasset M; Department of Bacteriology, CHU Dijon, Dijon, France.
  • Gaudart A; Department of Bacteriology, Hospices Civils Lyon, Lyon, France.
  • Georges M; Department of Respiratory Diseases, CHU Limoges, Limoges, France.
  • Godet C; Department of Bacteriology, CHU Nice, Nice, France.
  • Godreuil S; Department of Respiratory Diseases, CHU Dijon, Dijon, France.
  • Guillouzouic A; Department of Respiratory Diseases, CHU Poitiers, Poitiers, France.
  • Hamdad-Daoudi F; Department of Bacteriology, CHU Montpellier, Montpellier, France.
  • Héry-Arnaud G; Department of Bacteriology, CHU Nantes, Nantes, France.
  • Koebel C; Department of Bacteriology, CHU Amiens, Amiens, France.
  • Lagrange A; Department of Bacteriology, CHU Brest, Brest, France.
  • Lanotte P; Department of Bacteriology, CHRU Strasbourg, Strasbourg, France.
  • Marchand-Adam S; Department of Respiratory Diseases, Amiens University Hospital, CHU Amiens, 80054, Amiens Cedex 1, France.
  • Mougari F; Department of Bacteriology, CHU Tours, Tours, France.
  • Murris M; Department of Respiratory Diseases, CHU Tours, Tours, France.
  • Patry I; Department of Bacteriology, AP-HP, Paris, France.
  • Pérouse de Montclos M; Laboratoire Associé du Centre National de Référence des Mycobactéries et Résistance des Mycobactéries aux Antibiotiques (CNR-MyRMA), Paris, France.
  • Raskine L; Department of Respiratory Diseases, CHU Toulouse, Toulouse, France.
  • Risso K; Department of Bacteriology, CHU Besançon, Besançon, France.
  • Segonds C; Department of Bacteriology, Hospices Civils Lyon, Lyon, France.
  • Sicard D; Department of Bacteriology, AP-HP, Paris, France.
  • Terru D; Laboratoire Associé du Centre National de Référence des Mycobactéries et Résistance des Mycobactéries aux Antibiotiques (CNR-MyRMA), Paris, France.
  • Vachée A; Department of Respiratory Diseases, CHU Nice, Nice, France.
  • Vergnon JM; Department of Bacteriology, CHU Toulouse, Toulouse, France.
  • Martin C; Department of Bacteriology, CHU Nice, Nice, France.
  • Schramm F; Department of Bacteriology, CHU Montpellier, Montpellier, France.
BMC Pulm Med ; 21(1): 333, 2021 Oct 26.
Article em En | MEDLINE | ID: mdl-34702233
ABSTRACT

BACKGROUND:

Recent studies report very low adherence of practitioners to ATS/IDSA recommendations for the treatment of nontuberculous mycobacteria pulmonary disease (NTM-PD), as well as a great variability of practices. Type of management could impact prognosis.

METHODS:

To evaluate management and prognosis of patients with NTM-PD cases with respect to ATS recommendations, we conducted a multicenter retrospective cohort study (18 sentinel sites distributed throughout France), over a period of six years. We collected clinical, radiological, microbiological characteristics, management and outcome of the patients (especially death or not).

RESULTS:

477 patients with NTM-PD were included. Respiratory comorbidities were found in 68% of cases, tuberculosis sequelae in 31.4% of patients, and immunosuppression in 16.8% of cases. The three most common NTM species were Mycobacterium avium complex (60%), M. xenopi (20%) and M. kansasii (5.7%). Smear-positive was found in one third of NTM-PD. Nodulobronchiectatic forms were observed in 54.3% of cases, and cavitary forms in 19.1% of patients. Sixty-three percent of patients were treated, 72.4% of patients with smear-positive samples, and 57.5% of patients with smear-negative samples. Treatment was in adequacy with ATS guidelines in 73.5%. The 2-year mortality was 14.4%. In the Cox regression, treatment (HR = 0.51), age (HR = 1.02), and M. abscessus (3.19) appeared as the 3 significant independent prognostic factors.

CONCLUSION:

These findings highlight the adequacy between French practices and the ATS/IDSA guidelines. Treatment was associated with a better survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumopatias / Infecções por Mycobacterium Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Pulm Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumopatias / Infecções por Mycobacterium Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Pulm Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França